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Abstract
Background: Cervical cancer remains an important cause of cancer mortality for Mexican women. HPV 16/18
typing may help to improve cervical cancer screening. Here we present the prevalence of high-risk human
papillomavirus (hrHPV) including HPV16 and HPV18 from the FRIDA (Forwarding Research for Improved Detection
and Access) population.
Methods: Beginning in 2013, we recruited 30,829 women aged 30–64 in Tlaxcala, Mexico. Cervical samples were
collected and tested for 14 hrHPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). We used
logistic regression to estimate odds ratios with 95 % confidence intervals for hrHPV infections according to putative
risk factors.
Results: Prevalence of infection with any of the 14 hrHPV types was 11.0 %. The age-specific prevalence of all
hrHPV formed a U-shaped curve with a higher prevalence for women aged 30–39 and 50–64 than women aged
40–49. Across all age groups, 2.0 % of women were positive for HPV16 and/or HPV18 (HPV16/18), respectively.
HPV16/18 prevalence also showed a U-shaped curve with increased prevalence estimates for women aged both
30–39 and 60–64. Both prevalence curves had a significant quadratic age coefficient. Infections with hrHPV were
positively associated with an increased number of lifetime sexual partners, a history of sexually transmitted disease,
being unmarried, use of hormonal contraception, having a history of smoking and reported condom use in the
multivariate model.
Conclusions: The FRIDA population has a bimodal distribution of both hrHPV and HPV16/18 positivity with higher
prevalences at ages 30–39 and 60–64. These findings will help to evaluate triage algorithms based on HPV
genotyping.
Trial registration: The trial is registered with ClinicalTrials.gov, number NCT02510027.
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Background
Cervical cancer is the second most fatal cancer for
women in Mexico [1]. Chronic infection with high-risk
human papillomavirus (hrHPV), one of the world’s most
prevalent sexually transmitted infections (STIs), is a ne-
cessary cause of cervical cancer [2]. Over 100 types of
HPV have been established. Among these, 15 HPV types
are classified as carcinogenic or high risk (16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82) [3]. From
the point of view of cervical pathology, however, two
types—HPV16 and 18—account for the vast majority of
cervical cancer cases. Worldwide, HPV16 alone accounts
for almost 60 % of cases, and HPV18 accounts for an-
other 10 % of cases [4].
Because many countries in the developing world in-
cluding Mexico do not have reliable cancer registries, it
is difficult to ascertain the incidence of disease. Without
incidence rates, resource allocation cannot fully reflect
the differing needs of the various health districts. The
prevalence of hrHPV, particularly HPV16 and HPV18,
can be used as a valuable predictor of cervical cancer in-
cidence [5].
Wise resource allocation will become more important
as the cervical cancer prevention landscape in Mexico
shifts. In 2008, Mexico began using hrHPV testing in-
stead of cervical cytology for primary screening in the
public sector, and then in 2012, Mexico introduced a
universal HPV vaccination program for all girls in the
5th grade of elementary school [6]. The impact of the
vaccine, however, will not be seen for at least a gener-
ation, and therefore, research groups in Mexico and
throughout the developing world are seeking to establish
their cervical cancer screening program. At the current
time, Mexican health services cannot support a screen-
ing program in which all hrHPV positive women are
sent for further diagnostic work-up [7]. Indeed only a
small percentage of hrHPV positive women will actually
ever develop high grade cervical intraepithelial neoplasia
(CIN) [8].
To avoid overburdening the local services, researchers
are now working to identify a reliable triage testing strat-
egy for hrHPV positive women. While cytology seems to
be an obvious triage option given the existing infrastruc-
ture, we are also trying alternatives because of the diffi-
culty of maintaining high-quality cytology in Mexico [9].
One potentially important option for the triage of
hrHPV positive women would be to identify those posi-
tive for HPV16 and HPV18 for further evaluation and
diagnostic confirmation. Results of the Roche ATHENA
trial in the US demonstrate the strong promise of
HPV16/18 based triage strategies to increase diagnostic
efficiency without sacrificing sensitivity of disease detec-
tion [10]. Indeed Roche has recently received FDA ap-
proval for its test to triage HPV16/18 positive women
for diagnostic follow-up. The feasibility of a similar
screening strategy in Mexico will rest on the prevalence
of HPV16 and HPV18 and the positive predictive value
of these types for high grade CIN.
The prevalence of HPV16 and HPV18 within the gen-
eral population has not been well described in Mexico.
The last population-based study to report on the preva-
lence of HPV16 and HPV18 in Mexico was published
over a decade ago in 2001 [11]. More recent studies have
only looked at small convenience samples [12–14]. The
present study is part of a larger study, FRIDA (Forward-
ing Research for Improved Detection and Access), a
population-based demonstration project designed to
evaluate the performance and cost-effectiveness of triage
alternatives for cervical cancer screening in Tlaxcala,
Mexico. While a number of small studies have reported
on the type-specific prevalence of HPV16 and HPV18 in
Mexico [11–18], the present study is the largest to do so
with population-based representation.
Methods
Study population
We studied specimens and data from the FRIDA study,
an on-going population-based demonstration project
that began in Tlaxcala, Mexico in August 2013. Women
30 to 64 years of age living within our target health dis-
trict in Tlaxcala, Mexico are being recruited directly by
healthcare personnel within preventive, family planning
and gynecological health services during routine visits.
This target health district includes approximately 100
health care facilities. The complete FRIDA cohort is pro-
jected to include more than 80% of the target population
of over 100,000 women aged 30 to 64 years. Although
the Tlaxcala cervical cancer screening program continu-
ously invites women for screening at regular time inter-
vals, women are generally tested opportunistically, with
screening usually being initiated by the woman herself.
This preliminary analysis includes results from the
first 31,629 women enrolled in the demonstration
project who came to the the clinic health care set-
tings. Women then were invited at the clinic into the
study. Women who were pregnant or had had a hys-
terectomy were excluded, leaving a total of 30,829
women in the present analysis (Fig. 1).
The study proposal was reviewed and approved by the
research and ethics committees of the Instituto Nacional
de Salud Pública (INSP) (1094), Comisión Federal para
la Protección Contra Riesgos Sanitarios (CAS/OR/01/
CAS/123300410C0044-3578/2012) and Secretaría de
Salud del Estado de Tlaxcala (SS. DECI-OI-13/12). The
purpose and procedures of the study were explained to
all participants and informed verbal consent was
obtained.
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Procedures
Health care personnel conducted face-to-face interviews
of FRIDA study participants using pre-printed pen and
paper surveys designed to elicit details of sexual behav-
ior, history of STIs, parity, gynecologic and reproductive
health histories, and other probable risk factors for cer-
vical cancer.
Participants were then given a pelvic exam during
which a cervical sample was collected using a Cervex-
Brush® (Rovers®). This cervical sample was placed in a
ThinPrep® vial (Hologic, Inc., Bedford, MA) and then
0.4 mL tested for hrHPV using Roche’s cobas® 4800 sys-
tem. This assay uses a PCR-based in-vitro test for the
simultaneous detection of 14 hrHPV types (16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) in liquid
based cervical samples. The system detects HPV16 and
HPV18 individually, and the remaining 12 hrHPV
genotypes as a pool [19]. The testing was carried out at
the HPV laboratory at the INSP in Cuernavaca, Mexico ac-
cording to manufacturer’s instructions (Roche Diagnostics).
Statistical analysis
Descriptive statistics were used to characterize the vari-
ables. Age, age of sexual debut, parity, and number of
sexual partners were recorded as continuous, numeric
variables, and then analyzed as categorical variables.
Marital status, use of contraception (hormonal, IUD,
condoms), history of previous STIs, and smoking history
were both collected and analyzed as categorical vari-
ables. In the analysis, participants classified as hrHPV
positive tested positive for any of the 14 hrHPV types in-
cluding HPV16 and HPV18. Among these positives, par-
ticipants were then classified as positive for HPV16
regardless of whether or not they also tested positive for
another hrHPV type. Participants classified as positive
for HPV18 were treated in the same way. The designa-
tion “HPV16/18” refers to participants who tested posi-
tive for either HPV16, HPV18, or both, regardless of
other hrHPV types. The designation “HPV16/18 only”
means these participants tested positive for HPV16 and/
or HPV18, but no other hrHPV types. The “non-16/18
hrHPV only” group refers to women who tested positive
for other hrHPV types (31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 66, and 68), but neither HPV16 nor HPV18. The
“HPV16/18 and other hrHPV types” group tested posi-
tive for HPV16 and/or HPV18 as well as another hrHPV
type.
All pooled hrHPV, HPV16/18 only, non-16/18 hrHPV
only, and HPV16/18 and other hrHPV type prevalence
were estimated by age along with associated binomial
95 % confidence intervals (CI). Looking at the preva-
lence graphs by age categories, we decided to use a
quadratic model for log odds as a function of age. As-
suming that the quadratic models are approximately cor-
rect, the coefficient on age2 is a rough measure of the
steepness of the parabola. A formal test for differences
in steepness of curves for different hrHPV categories
was constructed by using the coefficient estimates and
their standard errors. Because the sample sizes are large,
a normal approximation was used.
We furthermore used logistic regression to compute
odds ratios (ORs) with 95 % CIs to identify independent
risk factors for hrHPV infections. ORs were adjusted for
age to account for differences in age-group prevalence
and for comparability with other population reports.
Variables associated with hrHPV infections were adjusted
Fig. 1 Flow Chart of hrHPV Screening of the FRIDA Study Population. Women 30 to 64 years of age living within our target health district were
invited by healthcare personnel. This study reports the results from the first 31,629 women who volunteered to participate in the Tlaxcala cervical
cancer screening program. Four-hundred and eighty-three women were excluded, leaving 30,829 who had hrHPV results available, in the current
analysis. Of those 30,829 women, 3,401 women were positive for hrHPV. Among those 3,401 women, 13.6 % were positive for HPV16, 5.9 % for
HPV18 and 1.1 % for both HPV16 and HPV18 coinfection. These three categories indicate positivity independent of the presence of other hrHPV
types. The last category of other high risk HPV types include women who tested positive for other hrHPV types (31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 66, and 68), but neither HPV16 nor HPV18
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for other covariates using multiple logistic regression ana-
lysis. Data analysis was conducted using STATA version
12.0 (StataCorp). A two-sided significance level of 0.05
was chosen to indicate statistical significance.
Results
Characteristics of the population
Nearly 97% of women who volunteered to participate in
the Tlaxcala cervical cancer screening program met the
inclusion study criteria. Approximately 31 % of the tar-
get population is included in this analysis. The distribu-
tion of ages screened does not perfectly reflect the target
population. A higher proportion of women aged 30 to
49 were screened than older groups in the population.
Approximately 3.4 % of women aged 60 to 64 were
screened. The mean age of the study population was
41.8 years (data not shown).
Approximately 90 % of participants were married, and
nearly two-thirds of participants were 18 or older when
they initiated sexual activity. The majority of participants
have been pregnant and almost 50 % report 3 or more
live births. The vast majority of the study participants
reported one lifetime sexual partner (71 %). A history of
oral contraceptive use was reported by about 21 % of
women and a little more than one-third (33 %) were
using an IUD. Most women (83 %) reported not using a
condom at all in the last 12 months. Histories of previ-
ous sexually transmitted infections were rare (3 %), and
about 3 % of women reported ever having smoked
(Table 1). Approximately 5.0 % self-reported a history of
abnormal cervical cytology (data not shown) and 24.9 %
of those women received treatment.
High risk HPV prevalence and risk profile
The estimated overall prevalence of hrHPV in this popu-
lation was 11.0 % (95 % CI 10.7–11.4). High risk HPV
DNA was detected in 13.7 % (95 % CI 12.9–14.5) of
women aged 30 to 34 and in 11.3 % (95 % CI 10.6–12.1)
of women aged 35 to 39. The prevalence estimates
declined to 9.4 % (95 % CI 8.7–10.2), 8.8 % (95 % CI
7.9–9.6), and 10.2 % (95 % CI 9.2–11.4) for women aged
40–44, 45–49, and 50–54, respectively. High risk HPV de-
tection then increased again to 11.4 % (95 % CI 10.1–12.9)
and 11.3 % (95 % CI 9.5–13.4) for women aged 55 to 59
and 60 to 64, respectively (Table 1 and Fig. 2). In the
multivariate model, women aged 30 to 39 were at higher
risk of hrHPV infection than women aged 45 to 49, the
reference group. The prevalence of hrHPV infections for
the oldest age group, women aged 55 to 64, was also sig-
nificantly different than the reference group, showing a
clear U-shaped curve. The coefficients on age2 were
significant.
In addition to age related risks, being unmarried, hav-
ing a history of oral contraceptive use, having a history
of smoking, condom use, having more than one lifetime
sexual partner, having two or more sexual partners in
the last year, and a history of another STI were also
found to be positively associated with hrHPV infections
in the multivariate model (p < 0.05). This model adjusted
for marital status, age at initiation of sexual intercourse,
number of lifetime sexual partners, number of sexual
partners in the last 12 months, history of hormonal
contraception, condom use in the last 12 months, a his-
tory of a previous STI, and tobacco use. Age of sexual
initiation was, significant only in the age adjusted model
(Table 1).
Prevalence of hrHPV Infections by Type in the total
screened population
Among all age groups, 9.0 % tested positive for non-16/
18 hrHPV only. The distribution by age group showed a
U-shaped curve with increased prevalence estimates for
women in their 30s and as well as for women over the
age of 50 (Table 2 and Fig. 3). The coefficients on age2
were significant (Table 3).
Among all age groups, 1.5 and 0.7 % were positive at
least for HPV16 and HPV18, respectively. By age group,
the prevalence of HPV16/18 was highest for the
youngest women in the population at 2.9 % (95 % CI
2.5–3.3) for ages 30–34 and 2.3 % (95 % CI 2.0–2.7) for
ages 35–39. Prevalence estimates then declined to 1.8 %
(95 % CI 1.5–2.1), 1.3 % (95 % CI 1.0–1.6), 1.4 % (95 %
CI 1.0–1.8), and 1.5 % (95 % CI 1.1–2.2) for ages 40–44,
45–49, 50–54, and 55–59 (Table 2 and Fig. 2). Estimates
then surge for women aged 60 to 64 to 2.2 % (95 % CI
1.5–3.3) (Table 2 and Fig. 2). The prevalence of HPV16
and HPV18 coinfection but neither hrHPV types was
rare (0.08 %) (data not shown). The distribution by age
group for women who only had HPV16/18 infections
showed a marked U-shaped curve with an initial in-
crease for women in their 30s, a decreased prevalence
for women in their 40s and 50s, and a second increase
in prevalence for women in their 60s (Table 2 and Fig. 3).
Like the other prevalence curves, the coefficients on
age2 for HPV16/18 only infections is highly significant
(Table 3).
Finally, the prevalence of coinfections with HPV16/18
and another hrHPV type was 0.7 %. The prevalence by
age showed a similar U-shaped curve with increased es-
timates for the younger and older women in the popula-
tion (Table 2 and Fig. 3). Again, this curve had a
significant quadratic trend (Table 3). Overall, there was
no significant difference between the quadratic terms for
HPV16/18 and the non-16/18 hrHPV only curve. Fur-
thermore, when the quadratic terms for HPV16/18 only
and non-16/18 hrHPV only were compared, there was
no significant difference (p < 0.05) (Table 3).
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Table 1 Associations between hrHPV and Reproductive Health and Behavior Variables
n (% of Total pop.
screened)
hrHPV n Prevalence hrHPV
(95 % CI)
Age Adjusted OR
(95 % CI)a
Multivariate Adjusted OR
(95 % CI)b
Age (years)
30–34 7,083 (23.0) 971 13.7 (12.9–14.5) 1.65 (1.46–1.87) 1.61 (1.42–1.83)
35–39 7,131 (23.1) 809 11.3 (10.6–12.1) 1.33 (1.17–1.51) 1.31 (1.15–1.49)
40–44 6,176 (20.0) 582 9.4 (8.7–10.2) 1.08 (0.95–1.24) 1.09 (0.95–1.25)
45–49 4,402 (14.3) 386 8.8 (7.9–9.6) 1 (ref) 1 (ref)
50–54 2,969 (9.6) 304 10.2 (9.2–11.4) 1.19 (1.01–1.39) 1.19 (1.01–1.40)
55–59 2,015 (6.5) 230 11.4 (10.1–12.9) 1.34 (1.28–1.59) 1.32 (1.11–1.58)
60–64 1,053 (3.4) 119 11.3 (9.5–13.4) 1.33 (1.07–1.65) 1.34 (1.07–1.68)
Total 30,829 3401 11.0 (10.7–11.4)
Marital Status
Unmarried 3, 362 (10.9) 600 17.9 (16.6–19.2) 1.96 (1.78–2.16) 1.65 (1.48–1.83)
Married/Civil Union 27,467 (89.1) 2,801 10.2 (9.8–10.6) 1 (ref) 1 (ref)
Age of Sexual Debut
≤17 11,221 (36.4) 1,333 11.9 (11.3–12.5) 1.13 (1.05–1.20) 1.04 (0.97–1.13)
≥18 19,591 (63.6) 2,067 10.6 (10.1–11.0) 1 (ref) 1 (ref)
Number of Lifetime Sexual Partnersc
1 partner 21,832 (70.8) 1,950 8.9 (8.6–9.3) 1 (ref) 1 (ref)
2 partners 5,910 (19.2) 879 14.9 (14.0–15.8) 1.77 (1.62–1.93) 1.61 (1.47–1.76)
≥3 partners 2,940 (9.5) 556 18.9 (17.5–20.4) 2.34 (2.11–2.59) 1.96 (1.75–2.19)
Number of Sexual Partners in the Last 12 Monthsc
0 partners 5,724 (18.6) 686 12.0 (11.2–12.9) 1 (ref) 1 (ref)
1 partner 24,792 (78.2) 2,659 10.7 (10.3–11.1) 0.87 (0.79–0.95) 0.96 (0.87–1.05)
≥2 partners 111 (0.4) 32 28.8 (21.2–37.9) 2.9 (1.90–4.41) 1.75 (1.13–2.70)
Parity
0 7,091 (23.1) 785 11.1 (10.4–11.8) 1 (ref)
1 or 2 8,511 (27.6) 967 11.4 (10.7–12.1) 1.04 (0.94–1.15)
3 or more 15,049 (48.8) 1,631 10.8 (10.4–11.3) 1.05 (0.96–1.16)
History of Hormonal Contraception
Yes 6,417 (20.8) 790 12.3 (11.5–13.1) 1.17 (1.07–1.27) 1.10 (1.01–1.20)
No 24,154 (78.1) 2,587 10.7 (10.3–11.1) 1 (ref) 1 (ref)
Current IUD Use
Yes 10,170 (33.0) 1,164 11.5 (10.8–12.1) 1.05 (0.98–1.14)
No 19,887 (64.5) 2,153 10.8 (10.4–11.3) 1 (ref)
Condom Use in the last 12 months
Never 25,557 (82.9) 2,682 10.5 (10.1–10.9) 1 (ref) 1 (ref)
Almost always 2,777 (9.0) 373 13.4 (12.2–14.8) 1.27 (1.13–1.43) 1.15 (1.01–1.29)
Always 1,716 (5.6) 253 14.7 (13.1–16.5) 1.42 (1.23–1.63) 1.26 (1.09–1.46)
History of a Previous STI
Yes 979 (3.2) 182 18.6 (16.3–21.1) 1.91 (1.62–2.25) 1.54 (1.30–1.84)
No 29,424 (95.4) 3,161 10.7 (10.4–11.1) 1 (ref) 1 (ref)
Tobacco Use
Never 29,238 (94.8) 3,160 10.8 (10.5–11.2) 1 (ref) 1 (ref)
Ever 964 (3.1) 175 18.2 (15.8–20.7) 1.77 (1.49–2.10) 1.23 (1.03–1.47)
Rudolph et al. BMC Infectious Diseases  (2016) 16:461 Page 5 of 10
Discussion
Our population-wide investigation provides a better rep-
resentation of exposure to infection than a clinic-based
population with abnormal cytology in whom HPV16 and
HPV18 would be over-represented. The present study is
not only the largest in Latin America and most current
population based study to date, but is also the first to
use Roche’s cobas® 4800 system for hrHPV analysis.
Roche’s cobas® 4800 system has been shown to be a
highly sensitive and specific test for the detection of
hrHPV as well as HPV16 and HPV18 [20].
There has only been one other previous large popula-
tion based study conducted in Mexico to report hrHPV
type specific prevalence estimates. Although this previ-
ous study used a different design and methodology, the
age distribution of hrHPV from this study shows a simi-
lar U-shaped curve with a first peak for the youngest
women and a second peak for the oldest age group [11].
A similar U-shaped curve was found in both the Guana-
caste cohort in Costa Rica [21] and a population of Co-
lombian women [22]. Outside of Latin America, a meta-
analysis of worldwide epidemiologic data also found this
same U-shaped curve for developing nations throughout
the world including Africa and Southeast Asia [23].
While the second peak of HPV infections for women up
to ages 30 to 39 has been seen in diverse populations
throughout the world [23, 24], in Central and South
America this peak appears to be more prominent. Epide-
miologic data suggests that this first peak of infection can
be correlated with sexual initiation in younger women
when they are exposed to HPV for the first time and their
adaptive immune response has yet to develop [8].
The second peak of infections for women ages 60 to
64 in the FRIDA population is again only seen mirrored
in populations throughout the developing world. In
North America and throughout most of Europe, the
prevalence of HPV infection declines consistently after
the initial peak associated with sexual debut [23]. The
reasons for this second peak of hrHPV DNA detection
are unknown. Current theories suggest that this second
peak may be the result of immune depression leading to
reactivation of previous quiescent infections [25, 26], the
Abbreviations: STI sexually transmitted infections, OR odds ratio, CI confidence interval
aOdds ratios for all the variables with the exception of age itself are adjusted for age. Age was included in the model as a categorical variable (30–34, 35–39, 40–44, 45–49,
50–54, 55–59, 60–64); bAssociation test was adjusted for age, marital status, age of sexual debut, number of lifetime sexual partners, number of sexual partners in the last
12 months, history of hormonal contraception, condom use in the last 12 months, history of a previous STI, and tobacco use; cWomen who reported zero lifetime sexual
partners were excluded
Statistically significant p values ≤ 0.05 of the OR's are marked in bold font
Fig. 2 Age Specific Prevalence of hrHPV and HPV16/18 with 95 % CI. The overall prevalence of hrHPV was 11.0 % in this population. Two percent
of women overall were positive for HPV16 and/or HPV18 (HPV16/18). The prevalence of hrHPV overall and HPV16/18 by age group both show a
bimodal distribution with an increased prevalence for the youngest women in the population aged 30–39 and a second bump of positivity for
the oldest women aged 60 and above
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acquisition of new hrHPV infections through changes in
sexual behavior on the part of the women themselves
and/or their partners, or a cohort effect [25, 27–29]. An-
other theory suggests that differences in screening pro-
grams may also play a role in the presence of this
second peak. In countries with effective screening pro-
grams, the removal of precancerous lesions is believed
to have an antigen-presenting effect to the immune sys-
tem that may help protect against future HPV infections
[30]. Based on this theory, in countries where screening
programs do not identify and treat these precancerous
lesions, women cannot benefit from this added immuno-
logic boost.
For the FRIDA population, the U-shaped prevalence
curve was also seen for HPV16/18 infections. This same
pattern is seen in the Guanacaste cohort in Costa Rica
[21] and in the previous Mexican study for HPV16, but
not for HPV18 [11]. Overall, point estimates of HPV16/
18 prevalence appear higher in other study populations
throughout Latin America [9, 21, 23, 31], but due to dif-
ferent study designs, it is difficult to draw conclusions
concerning the comparative burden of infections.
In addition to the differences seen among age groups,
multiple sexual partners was found to be a risk factor for
hrHPV infection. Other studies have found a similar
association between an increased number of sexual
Table 2 Type Specific Prevalence of hrHPV by Age
Age (years) Total pop. HPV16/18a Non-16/18 hrHPV only HPV16/18 only HPV16/18 and
Non-16/18 hrHPV
% (95 % CI) % (95 % CI) % (95 % CI) % (95 % CI)
30–34 7,083 2.9 (2.5–3.3) 10.8 (10.1–11.5) 1.8 (1.5–2.2) 1.1 (0.9–1.4)
35–39 7,131 2.3 (2.0–2.7) 9.1 (8.4–9.7) 1.5 (1.2–1.8) 0.8 (0.6–1.1)
40–44 6,176 1.8 (1.5–2.1) 7.7 (7.0–8.3) 1.3 (1.0–1.6) 0.5 (0.3–0.7)
45–49 4,402 1.3 (1.0–1.6) 7.5 (6.8–8.3) 0.8 (0.6–1.2) 0.4 (0.3–0.7)
50–54 2,969 1.4 (1.0–1.8) 8.9 (7.9–10.0) 0.6 (0.4–1.0) 0.7 (0.5–1.1)
55–59 2,015 1.5 (1.1–2.2) 9.9 (8.6–11.3) 0.9 (0.6–1.5) 0.6 (0.3–1.0)
60–64 1053 2.2 (1.5–3.3) 9.1 (7.5–11.0) 1.1 (0.7–2.0) 1.0 (0.6–1.9)
Total 30,829 2.0 (1.9–2.2) 9.0 (8.7–9.3) 1.3 (1.2–1.4) 0.7 (0.6–0.8)
Abbreviations: CI confidence interval
aHPV16/18 refers to women who are positive for HPV16 and/or 18 regardless of other hrHPV types for which they may or may not test positiv
Fig. 3 Age Specific Prevalence of hrHPV Types with 95 % CI. The cobas® 4800 system delivers hrHPV results in three categories: HPV16, HPV18,
and other hrHPV. Based on these results, we divided the population into three mutually exclusive categories: (1) women positive for only other
hrHPV (non-16/18 hrHPV only), (2) women positive for HPV16 and/or HPV18 (HPV16/18), and (3) women positive for HPV16 and/18 as well as
another hrHPV (HPV16/18 + other hrHPV). The prevalence of these three categories by age group shows a similar bimodal distribution with
increased prevalence values for the youngest and oldest women in the population
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partners and risk of hrHPV infection [26, 32, 33]. In
contrast, age at first intercourse was not found to be an
independent risk factor for hrHPV in this population,
similar to other studies. However, we also acknowledge
that there are previous studies reporting that the age of
sexual debut is an independent risk factor by itself [34].
It should be noted that a particularity of FRIDA popula-
tion was a younger age of sexual debut was highly corre-
lated with having more than one lifetime sexual partner
(p < 0.001) (data not shown).
This preliminary analysis only contains 30 % of the
target population. With a larger population, our study
will be better powered to describe HPV16/18 determi-
nants. We furthermore acknowledge the possibility of
social desirability bias with the sensitive, self-reported
data, such a bias may have led to underestimation of cer-
tain risk factors. We attempted to limit such bias by pro-
viding a private space for the recruitment interviews.
In the absence of cervical screening or cancer regis-
tries in Mexico at the national, regional or state levels,
these prevalence data can help to better inform resource
allocation decisions. Sharma et al. developed a model
whereby hrHPV prevalence data can be used to estimate
cervical cancer risk [5]. While Sharma et al.’s models
have been developed to predict cervical cancer incidence
in developed countries, more data is needed in develop-
ing countries such as Mexico to refine these models so
they can be better applied in the developing world [5].
Such a reliable model to determine cervical cancer risk
would be a very valuable tool in Mexico and through the
developing world. Nonetheless, it is important to note
that the generalizability of the findings may be limited
both within Mexico and outside of Mexico.
Beyond predicting cervical cancer risk, the prevalence
data from this study can serve a number of additional uses
from a policy perspective. First the prevalence information
can be useful for evaluating the impact of HPV vaccination
over the long term. While a number of surrogate end-
points of vaccine impact may be used, HPV type-specific
prevalence data has become the standard early indicator of
choice [35, 36], and thus these prevalence data may also
be used as baseline to monitor vaccine effectiveness.
This prevalence information will furthermore be useful
for policymakers trying to determine the best triage prac-
tices in Mexico. In 2013, our study group was able to
show that primary screening for hrHPV is effective, but a
secondary follow-up or triage test is needed to determine
which women should be sent to colposcopy [7]. We
attempted to send all hrHPV positive women to colpos-
copy, but found it was not only inefficient, but also over-
burdened the local health services. In this previous pilot,
we sent nearly 11 % of women for colposcopy services. If
we had triaged women based on HPV16/18, we would
have only sent 2 % of women and still detected more than
70 % of disease [4]. Furthermore, some analyses suggest
that the best alternative may be a combination of triage al-
ternatives to offer high joint specificity to detect CIN2 or
more, including other triage tests such as cytology, p16 or
DNA methylation or at least evidence of 6 to 12 months
of persistent hrHPV infection before referral [37]. A triage
algorithm using HPV16/18 testing has been validated in
the US [10], but needs to be further explored in Mexico.
This prevalence data will help policymakers to determine
whether or not the current infrastructure in Mexico can
support the triage of HPV16 and HPV18 positive women.
Further study is still needed to determine the performance
and cost-effectiveness of HPV16 and HPV18 detection as
an additional triage alternative for hrHPV positive women,
and what additional testing may be required to ensure a
more effective and safe cervical cancer screening program
in Mexico.
The main strength of our study is our large, population-
based approach. This is the first study in Mexico of this
size to assess the prevalence of HPV16/18. This epidemio-
logic data will contribute to the creation of a more reliable
strategy of cervical cancer prevention in Mexico.
Conclusion
This sub-analysis of the FRIDA study demonstrates the
population level prevalence pattern of hrHPV and
HPV16/18 by age in Mexico. Both hrHPV and HPV16/
18 positivity have a bimodal distribution by age with
higher prevalences at ages 30–39 and 60–64. Infections
with hrHPV were also found to be positively associated
Table 3 Quadratic Model for Log Odds of hrHPV and hrHPV by Type
Coef. on age2
(SD)
Coef. on age
(SD)
Model
p value
Two-tailed P values for Differences
in Coefficient on Age2
Any hrHPV 0.00178 (0.000299) −0.1702 (0.0204) <0.001
HPV16/18a 0.00228 (0.000520) −0.2302 (0.0458) <0.001 0.206b
Non-16/18 hrHPV only 0.00155 (0.000250) −0.1449 (0.0223) <0.001
HPV16/18 only 0.00147 (0.000681) −0.1628 (0.0594) 0.031 1.098c
HPV16/18 and other hrHPV 0.00342 (0.000805) −0.3246 (0.0717) <0.001
Abbreviation: SD standard deviation
aHPV16/18 refers to women who are positive for HPV16 and/or 18 regardless of other hrHPV types for which they may or may not test positive; bcomparison non-
16/18 hrHPV only vs HPV16/18; c comparison non-16/18 hrHPV only vs HPV16/18 only
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with an increased number of lifetime sexual partners, a
history of STIs, being unmarried, use of hormonal
contraception, and reported condom use. Our results set
the stage for an improved cervical cancer screening
strategy in Mexico. While primary screening for hrHPV
has already been instituted in Mexico, this prevalence
data suggests the feasibility of HPV typing as an add-
itional screening parameter nationwide.
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